Category: Gilead

The Accept Phase Ib/II Single Arm Study

Oral and Poster Abstracts 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III Research, clinical trials, Lymphomas, Clinical Research, Combination therapy, Diseases, aggressive lymphoma, Therapies, Lymphoid Malignancies Andrew J Davies, BSc, BM, FRCP, PhD1,2*, Josh Caddy, BSc3*, Katy McLaughlin, BSc3*, Christopher Wignall, MSc3*, Robert…

Continue Reading The Accept Phase Ib/II Single Arm Study

Intellia: Slim Hopes Of Near-Term Commercial Revenue, Bearish

liulolo/iStock via Getty Images Investment Thesis If you had invested in the CRISPR / Cas9 gene editing pioneer Intellia Therapeutics (NASDAQ:NTLA) five years ago, you would likely be well satisfied with your return to date – a ~285% return on your investment – although you may also feel that it…

Continue Reading Intellia: Slim Hopes Of Near-Term Commercial Revenue, Bearish

Caribou Biosciences Announces – GuruFocus.com

BERKELEY, Calif., May 11, 2022 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. ( CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of David L. Johnson to its board of directors. Mr. Johnson is a seasoned executive with 30 years of commercial and operational experience in the biopharmaceutical…

Continue Reading Caribou Biosciences Announces – GuruFocus.com

TwinEQTL: Ultra Fast and Powerful Association Analysis for eQTL and GWAS in Twin Studies

doi: 10.1093/genetics/iyac088. Online ahead of print. Affiliations Expand Affiliations 1 Department of Biostatistics, University of North Carolina, Chapel Hill, NC 27599, USA. 2 Department of Psychiatry, University of North Carolina, Chapel Hill, NC 27599, USA. 3 Department of Psychiatry, University of Utah, Salt Lake City, UT 84108, USA. 4 Gilead…

Continue Reading TwinEQTL: Ultra Fast and Powerful Association Analysis for eQTL and GWAS in Twin Studies